Kewaunee Scientific CEO Thomas Hull sells 1,425 shares in two transactions.

Kewaunee Scientific Corp /DE/[KEQU] announces that Director, President, and CEO Thomas David Hull III has executed a sale of 652 shares at $46 per share on September 18, 2025, and a sale of 773 shares at $45.34 per share on September 19, 2025.

Kewaunee Scientific Corp (KEQU) announced that its Director, President, and CEO, Thomas David Hull III, executed a sale of 652 shares at $46 per share on September 18, 2025, and a sale of 773 shares at $45.34 per share on September 19, 2025. These transactions come amidst a period of significant technical indicators suggesting a downward trend in the stock price.

On September 16, 2025, Kewaunee Scientific's 15-minute chart exhibited a MACD Death Cross, KDJ Death Cross, and a Bearish Marubozu Kewaunee Scientific's 15min chart triggers MACD Death ...^[1]. These indicators collectively signal a shift in market momentum, suggesting that the downward trend in Kewaunee Scientific's stock price is likely to persist. The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a bearish trend. The KDJ Death Cross, a combination of the K line and D line on the KDJ indicator, also signals a bearish trend. The Bearish Marubozu, characterized by a long white candle with no wicks, signifies that sellers are in control of the market.

Despite the company reporting strong top and bottom-line growth, with sales increasing by 46.9% to $71.1 million and net earnings rising 41.1% to $3.1 million, the stock has significantly underperformed the broader market. The domestic sales soared 53% to $54.4 million, while international sales advanced 30.2% to $16.8 million. The integration of Nu Aire, a Minnesota-based manufacturer of biological safety cabinets, incubators, and ultralow freezers, has contributed to this growth, with domestic sales and earnings significantly boosted by the acquisition Kewaunee Scientific's 15min chart triggers MACD Death ...^[1].

Institutional investors have been active in Kewaunee Scientific's stock, with notable increases in positions by various hedge funds. Punch & Associates Investment Management Inc. acquired a new stake in the first quarter, increasing its ownership to 0.70% of the company's stock. American Century Companies Inc., Ritholtz Wealth Management, and OMERS Administration Corp also boosted their stakes in the company during the first quarter .

CEO Thomas D. Hull III acknowledged the strong quarterly results while cautioning about the uneven quarterly performance expected through fiscal 2026 due to volatility in project delivery timelines. Management reiterated its commitment to growth, both organically and through acquisitions, supported by investments in people, processes, and technology Kewaunee Scientific's 15min chart triggers MACD Death ...^[1].

The recent technical indicators and the CEO's share sales suggest a cautious outlook for Kewaunee Scientific's stock price. Investors should closely monitor the company's progress and the broader market conditions to gauge the potential impact on the stock price.